

## CURRICULUM VITAE

(revised June 2008)

Name: Robert Bona

Business Address: University of Connecticut Health Center  
Section Hematology-Oncology  
263 Farmington Avenue  
Farmington, CT 06030-1315

Telephone: (860) 679-2255  
Telefax: (860) 679-4451  
E-mail: Bona@UP.UCHC.EDU

### **Education**

1973-1976 St. John's University, Jamaica, N.Y. B.S. Degree (Biology and Chemistry)  
Cum laude  
1976-1980 S.U.N.Y. Upstate Medical College, Syracuse, N.Y. M.D. Degree

### **Postgraduate Training**

July 1980-June 1981 Medical Internship, Brown University  
Rhode Island Hospital, Providence, R.I.  
July 1981-June 1983 Medical Resident, Brown University,  
Rhode Island Hospital, Providence, R.I.  
July 1983-June 1986 Fellow in Hematology-Oncology  
University of Connecticut Health Center  
Farmington, Connecticut  
June-August 1990 Training in Clinical Thrombosis  
McMaster University, Hamilton, Ontario

### **Certifications and Licenses**

1981 National Board of Medical Examiners  
1983 Diplomate: Internal Medicine 092633  
1985 Connecticut Licensure 026000  
1985 Diplomate: Medical Oncology  
1986 Diplomate: Hematology

### **Work Experience**

1986-1997 – Attending Physician, St. Francis Hospital and Medical Center, Hartford, CT

1997-present Attending Physician, University of Connecticut Health Center, Farmington, CT

### **Academic Appointments**

July 1985 - Instructor in Internal Medicine, University of Connecticut Health Center  
July 1986 - Assistant Professor of Medicine, University of Connecticut Health Center  
September 1994 - Associate Professor of Medicine, University of Connecticut Health Center  
September 2001 - Professor of Medicine, University of Connecticut Health Center

### **Saint Francis Hospital and Medical Center Appointments**

December 1987 Assistant Attending Staff, St. Francis Hospital and Medical Center  
September 1990- Medical Director, Coagulation Laboratory  
June 1997  
September 1990- Associate Member, Department of Pathology  
June 1997  
November 1995- Associate Attending Staff  
June 1997

### **John Dempsey Hospital/ U Connecticut Medical School Appointments**

January 1987 Assistant Director, Hemophilia Treatment Center  
September 1992 Director, Hemophilia Treatment Center  
July 1997- Attending Physician in Hematology-Oncology/BMT  
July 1997- Hematology-Oncology Fellowship Program Director  
June 1998- Director, Anticoagulation Service  
May 1999- In Patient Course Director, 3<sup>rd</sup> Year Medical Student Clerkship  
June 2000- Multidisciplinary Ambulatory Experience Homeweeek, Director  
October 2001- Division Chief, Hematology-Oncology, UCHC  
October 2001- Associate Director (Clinical) UCHC Cancer Center  
July 2004- Section Leader – Homeostasis Section (7 week course for second year medical students) of Mechanism of Disease

### **Other Teaching and Clinical Responsibilities**

1. Attend on the In Patient and Consult Hematology-Oncology Service
2. Attend Hematology Clinic – precept fellows and residents
3. Teach in MSI Human Biology and Organ Systems
4. Teach in MSII Hematology and Oncology Sections
5. Small Group Seminars to Fellows, Residents, and Students regularly

## **Awards and Honors:**

- 1990 Thomas R. Preston, M.D. Award for Excellence in the Teaching of Internal Medicine, St. Francis Hospital and Medical Center;
- 1997 Director's Award. St. Francis Hospital and Medical Center;
- University of Connecticut School of Medicine "Outstanding Teaching Award" presented by the second year medical/dental school class. 1997, 1999, 2000, 2001, 2003-05, 2007;
- University of Connecticut School of Medicine "Loeser Teaching Award" for excellence in the teaching of basic sciences, 2000, 2006;
- Named to Best Doctors in Connecticut 2000, 01,02,03,04,05,06,07,08;
- 2001 Physicians Health Services-American Red Cross Chair;
- Named to Best Doctors in America, 2003, 04, 05, 06, 07,08;
- University of Connecticut School of Medicine "Kaiser Permanente Certificate of Award" for teaching in the clinical sciences, 2004, 2005;
- University of Connecticut School of Medicine, "CAMEL Award" given to best 2nd year course. 2005, 2006, 2007, 2008.
- 2006 Certificate of Excellence – University of Massachusettes Macy Mentorship Program in Health Communication Education;
- University of Connecticut School of Medicine, Kaiser Permanent Award given for excellence in clinical teaching, 2007,2008.
- 2007 Mace Bearer - University of Connecticut School of Medicine Commencement.

## **Grants**

- 1985 V.A. Career Development Awards: Associate Investigator  
"Monocyte Tissue Factor As a Regulator of Fibrin Deposition in Inflammation and Neoplasia" \$30,000
- 1986 Saint Francis Hospital and Medical Center: Program and Project Review Committee - Institutional Grant "The Potential Role of Tissue Factor-Factor VII Binding in the Hypercoagulable State of Cancer" \$17,575.00
- 1987 Faculty Research Grant 1987 University of Connecticut Health Center "Expression of Tissue Factor on Phospholipid Surfaces and its Interaction with Factor VII " \$1,530.00
- 1991 Biomedical Research Grant, St. Francis Hospital and Medical Center "Evaluation of the Molecular Defects in Type I Protein S Deficiency" \$5,400.00
- 1992- Care and Complications of Patients with Hemophilia and Other Bleeding Disorders – CDC and MCHB - \$64,000/year.
- 2006-07 Connecticut Sickle Cell Consortium: Lifespan Approach  
State of Connecticut Department of Public Health, Sickle Cell Disease Initiative  
Role: Co-Investigator (P.I. Roger Thrall)

## **Clinical Research**

Local Principle Investigator on the following clinical trials:

1. Comparison of the Efficacy and Safety of Subcutaneous RD Heparin versus Unfractionated Heparin for the Prevention of Deep Venous Thrombosis in Patients Undergoing Abdominal or Pelvic Surgery for Cancer, sponsored by Wyeth-Ayerst Research, 1991-92.

2. Multiple Dose, Double Blind Clinical Trial of The Safety and Efficacy of Enoxaparin for the Prevention of Post-Operative Deep Venous Thrombosis Following Total Hip Replacement Surgery, sponsored by Rhone-Poulenc Pharmaceuticals, 1991-92.
3. A Phase IV Evaluation of the Chronic Use of Monoclate Compared to Standard Anti-Hemophilic Factor Therapy in HIV Infected Patients with Moderate or Severe Hemophilia, sponsored by Rorer Pharmaceuticals, 1991-93.
4. Emergency Use of Ancrod as an Anticoagulant for Patients with Heparin Induced Thrombocytopenia, sponsored by Knoll Pharmaceuticals, 1991-94.
5. Multiple Dose, Open-Label, Clinical Trial of the Safety and Efficacy of Enoxaparin Compared to Unfractionated Heparin for the Prevention of Post-Operative Venous Thromboembolism Following Total Knee Replacement, sponsored by Rhone-Poulenc Rorer Central Research, 1991-93.
6. A Double Blind Dose Ranging Comparison of the Safety and Efficacy of Subcutaneous Normiflo Versus Warfarin for the Prevention of Deep-Vein Thrombosis in Patients Undergoing Knee Replacement Surgery, sponsored by Wyeth-Ayerst Research, 1992-94.
7. A Randomized, Open-Label, Parallel Group Comparison of the Safety and Efficacy of Lovenox (Enoxaparin) Injection vs. Coumadin in the Prevention of Thromboembolic Disease Following Hip Replacement Surgery, sponsored by Rhone-Poulenc Rorer, 1994-96.
8. A Multi-Center, Randomized, Partially Blind, Parallel Group, Clinical Trial to Compare the Efficacy and Safety of Twice and Once Daily Subcutaneously Administered Enoxaparin and Continuous Infusion Heparin in the Treatment of Patients with Deep Vein Thrombosis with or without Pulmonary Embolism, sponsored by Rhone-Poulenc Rorer, 1994-96.
9. Double Blind Placebo Controlled Clinical Trial Comparing the Efficacy and Safety of Prolonged Outpatient Enoxaparin and Placebo Therapies in the Prevention of Venous Thromboembolic Disease in Patients Undergoing Elective Primary Hip or Knee Replacement, sponsored by Rhone-Poulenc Rorer, 1994-96.
10. An Open Protocol for the Use of Anegralide for Thrombocytopenia, sponsored by Roberts Pharmaceuticals, 1993-97.
11. An Open Label Study of NOVASTANR (brand of argatroban) in Patients with Heparin Induced Thrombocytopenia (HIT) or Heparin Induced Thrombocytopenia and Thrombosis Syndrome (HITTS), 1995-97.
12. Randomized Comparison of Low Molecular Weight Heparin Versus Oral Anticoagulant Therapy for Long Term Anticoagulation in Cancer Patients with Venous Thromboembolism, Sponsored by Pharmacia & Upjohn, 2000.
13. Universal Data and Serum Specimen Collection for Patients with Hemophilia and Other Bleeding Disorders, sponsored by the Centers for Disease Control and Prevention, 1999-ongoing.

14. Non-myeloablative therapy followed by adoptive immunotherapy with allogeneic, HLA matched hematopoietic stem cell transplantation in the treatment of hematological malignancies, 1999-2001.
15. Epidemiology and Treatment of Circulating Anticoagulants in Patients with Hemophilia and von Willebrand's Disease – The Hemophilia Research Society Registry (HRS). 2004-

### **Data Monitoring Safety Boards**

1. A Randomized, Double-blind, Placebo-Controlled Study of Apixaban for the Prevention of Thromboembolic Events in Patients Undergoing Treatment for Advanced Cancer: A Phase 2 Pilot Study, Member 2007-
2. Phase II Study of Bevacizumab in Combination with Carboplatin and Paclitaxel in Patients with Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma. Chairperson. 2007-

### **Major Committee Assignments**

#### **St. Francis Hospital Committees**

1987-1989	Audit Committee
1989-1997	Curriculum Committee
1989-1990	Transfusion Committee
1990-1997	Chairman, Transfusion Committee
1992-1994	Chairman, Research Committee
1992-1996	Dept. of Medicine Representative to the Medical and Dental Staff Council
1994-1997	Research Committee
1995-1997	Pharmacy and Therapeutics Committee

#### **University of Connecticut Committees**

1996-1999	Committee for Undergraduate Medical Education
1998-	Chairperson, Transfusion Committee
1998-2004	Admissions Committee, Member
1998-	Curriculum Operating Committee
2001-2003	Compensation Appeals Committee, Chairperson
2003-2004	Compensation Appeals Committee, Member
2003-2004	Professionalism in Medicine Task Force, Chairperson
2003-	Human Systems Implementation Committee
2003-	Human Systems Grading Committee
2004-2005	Scientific Advisory Committee – GCRC
2004-2006	S.O.M. By-Laws Revision Committee
2005-2008	Oversight Committee (Chair 2007-08)
2005-	Cancer Center Executive Committee
2006-	Institutional Review Board

## **Professional Organizations**

1987	American College of Physicians, Member
1987-1990	Medical Advisory Board, National Hemophilia Foundation, Connecticut Chapter
1990-1995	Co-Chairperson, Medical Advisory Board, National Hemophilia Foundation, Connecticut Chapter
1987	American Society of Clinical Oncology
1987	Council on Thrombosis/American Heart Association
1988	American Society of Hematology
1988-1995	American Federation of Clinical Research
1988-1994	Professional Advisory Committee, East Hartford Visiting Nurse and Home Care Association
1988-1993	Steering Committee: Sickle Cell Service, St. Francis Hospital
1989-1990	Volunteer Hospice Physician, East Hartford Visiting Nurse and Homecare Association
1991	American College of Physicians, Fellow
1992-	Executive Committee, Region I National Hemophilia Foundation
1994-1998	International Academy of Clinical and Applied Thrombosis/Hemostasis
1995-2000	American Association of Blood Banks, Member
2001-	Hemophilia Thrombophilia Research Society of America, Thrombosis Committee
2001-2006	Fellow, American Heart Association, Council on Arteriosclerosis, Thrombosis, and Vascular Biology
2005-07.	Chairperson, Executive Committee, Region I, National Hemophilia Foundation
2007- Training	American Society of Hematology, Test Development Materials Committee - In Hematology Examination

## **Invited National/International Presentations**

1. Bona RD, Lee EJ, Rickles FR, Transport of Tissue Factor to Membrane Vesicles: Role of n-Linked Glycosylation, American Association of Clinical Research, Washington, D.C. 1986.
2. Bona RD, Weinstein RE, Walker FJ. Pseudo Protein S Deficiency Due to a Defect in C4bp. American Society of Hematology, Boston, MA 1990 (November).
3. International Society of Thrombosis and Hemostasis, Subcommittee on Cancer and Thrombosis, Venous Thromboembolism and Gliomas, New York, 1993
4. International Society of Thrombosis and Hemostasis, Subcommittee on Cancer and Thrombosis, Complications of Oral Anticoagulants in Cancer Patients, Brussels, Belgium 1994
5. International Society of Thrombosis and Hemostasis, Plenary Session, Treatment of Venous Thromboembolism in Cancer Patients, Florence Italy, 1997.
6. 1<sup>st</sup> International INATE Investigator's Meeting. Catheter Associated Central Vein Thrombosis in Cancer Patients, Barcelona, Spain, 2001.
7. Connecticut Academy of Family Practice Annual Meeting, Hypercoagulable States, 2002
8. Transfusion Medicine Update, New Therapeutic Options in Thrombosis and Hemostasis: What

Should the Blood Banker Know, Worcester, MA 2002

9. Connecticut Academy of Family Practice Annual Meeting, Updates in Treatment and Diagnosis of Venous Thromboembolism, 2003.

### **Consensus Conference**

Transfusion Medicine Update: Platelet Transfusion: A Consensus Development Conference Vol 7, No. 1, August 1994. Member planning committee.

### **Book Chapters**

1. Amy Hickey, Donna Wallace, Robert Bona, Managing the Cancer Patient, in Managing Oral Anticoagulation-The Development of an Anticoagulation Management Service, Jack Ansell, Lynn Oertel, and Ann Wittkowsky (eds), Aspen Publishers, Inc. 4B-10:1,1997
2. Amy Hickey, Donna Wallace, Robert Bona, Managing the Cancer Patient, in Managing Oral Anticoagulation-The Development of an Anticoagulation Management Service, Jack Ansell, Lynn Oertel, and Ann Wittkowsky (eds), Aspen Publishers, Inc. 4B-10:1, Supplement #1, October 1998.
3. Robert Bona, Management and Diagnosis of Bleeding in the Dental Patient, in Medical Emergencies in Dentistry, Bennett and Rosenberg (eds), McGraw Hill, 2002, pp.283-92.
4. Robert Bona, Amy Hickey, Donna Wallace. Managing the Patient with Cancer, in Managing Oral Anticoagulation Therapy – Clinical and Operational Guidelines, Jack Ansell, Lynn Oertel, and Ann Wittkowsky (eds), Aspen Publishers, Inc. 38:1-4 , 2003.

### **Publications: Peer Reviewed Journals**

1. Bona RD, Pasquale DN, Kalish R, and Witter BA. The Role of Porcine Factor VIII Combined with Plasmaphoresis in the Management of Hemophilic Patients with Inhibitors, Am. J. Hem 21:201-207,1986.
2. Schneiderman HS, Garibaldi RA, and Bona RD. Progressive Pulmonary Infiltrates in a Man with Erythroleukemia, Connecticut Medicine 50:443-47,1986.
3. Bona RD, Lee EJ, Rickles FR. Tissue Factor Apoprotein: Intracellular Transport and Expression in Shed Membrane Vesicles, Thrombosis Research 48:487-500,1987.
4. Bona RD, Von Willebrand Factor and von Willebrand's Disease: A Complex Protein and a Complex Disease, Annals of Clinical and Laboratory Science 19:184-189,1989.
5. Bona RD, Weinstein RE, Weisman S, Bartolomeo A, and Rickles FR, The Use of Continuous Infusion of Factor Concentrates in the Treatment of Hemophilia Patients, Am. J. Hem 32:8-13,1989.
6. Weinstein RE, Bona RD, Altman AJ, Quinn JJ, Weisman SJ, Bartolomeo A, Rickles FR, Severe Hyponatremia After Repeated Intravenous Administration of Desmopressin, Am. J. Hem. 32:258-61,1989.

7. Edwards RL, Klaus M, Matthews EM, McCullen C, Bona RD, and Rickles FR, Activation of Coagulation in Patients with Cancer: Heparin Abolishes the Chemotherapy Induced Increase in Plasma Fibrinopeptide A Levels and Fibrinopeptide Generation, *Am. J. Medicine*, 89,25-28,1990.
8. Weinstein RE, Bona RD, Rickles FR. Continuous Infusion of Monoclonal Antibody Purified Factor VIII. *Am. J. Hem*, 36:211-212,1991.
9. Dhami MS and Bona RD. Using Anticoagulants Safely. Guidelines for therapeutic and prophylactic regimens. *Postgraduate Medicine* 90:121-132,1991.
10. Ginsburg JS, Caco C, Brill-Edwards P, Panju A, Bona RD, Demers C, Tutters L, Nugent P, McGinnis J, Grant B, and Vander Lander Vries M. Venous Thrombosis in Patients Who Have Undergone Major Hip or Knee Surgery: Detection with Compression US and Impedance Plethysmography. *Radiology* 1991;181:651-54.
11. Bryan J Clarke, Frederick A. Ofofu, Sampath Sridhara, Robert D. Bona, Frederick R. Rickles, and Morris A. Blajchman. The First Epidermal Growth Factor-Like Domain of Human Coagulation Factor VII is Essential for Complex Formation with Tissue Factor, *FEBS* 298, 206-210,1992.
12. Ginsburg JS, Brill-Edwards P, Burrows RF, Bona R, Prandoni P, Buller HR, Lensing A. Venous Thrombosis During Pregnancy: Leg and Trimester of Presentation, *Thrombosis and Haemostasis*, 6,519-20,1992.
13. Parke AL, Weinstein RE, Bona RD, Maier DB, and Walker FJ. The Thrombotic Diathesis Associated with the Presence of Antiphospholipid Antibodies May Be Due to Low Levels of Free Protein S, *American Journal of Medicine*, 93,49-56,1992.
14. RD Bona, M Riberio, AU Klatsky, S Panek, M Magnifico, and FR Rickles. Continuous Infusion of Porcine Factor VIII for the Treatment of Patients with Factor VIII Inhibitors, *Seminars in Hematology*, 30(2) Supplement. 1:32-35,1993.
15. Dhami Mandeep, Bona R. Cancer and Thrombosis: Etiology, Diagnosis and Treatment, *Postgraduate Medicine*, 93:131-42,1993.
16. J.S. Ginsberg, C. Demers. P. Brill-Edwards, M. Johnston, R. Bona R.F. Burrows, J. Weitz, J.A. Denburg. Increased Thrombin Generation and Activity in Patients with Systemic Lupus Erythematosus and Anticardiolipin Antibodies; Evidence for a Prothrombotic State, *Blood*, 81;2958-63,1993.
17. E. Morse, S Panek, P. Pisciotto, T Kiraly, R Bona, K Vose, and FR Rickles. Reemergence of the INR (International Normalized Ratio), *Ann of Clin and Lab Sci* 23:184-88,1993.
18. M Dhami, RD Bona, J Colagero, RM Hellman. Venous Thromboembolism and High Grade Gliomas, *Thrombosis and Haemostasis* 70:393-96,1993.
19. Stephanie V. Seremetis, Louis M. Aledort, Garrett E. Bergman, Robert Bona, Gordon Bray, Doreen Brettler, M. Elaine Eyster, Craig Kessler, Tai-Shing Lau, Jeanne Lusher, Frederick Rickles. A Three Year Randomized Prospective Study of High or Intermediate Purity Factor VIII Concentrates

in Asymptomatic HIV+ Hemophiliacs: Effects on Immune Status, *Lancet* 342:700-03,1993.

20. Hanna WT, Bona RD, Zimmerman CE, Carta CA, Hebert GZ, Rickles FR. The Use of Intermediate Factor VIII Products in the Treatment of von Willebrand Disease, *Thrombosis and Haemostasis* 71:173-79,1994.
21. Spiro TE, Johnson GJ, Christie MJ, Lyons RM, MacFarlane DE, Blaiser RB, Tremaine MD, and the Enoxaparin Clinical Trial Group. Efficacy and Safety of Enoxaparin to Prevent Deep Venous Thrombosis After Hip Replacement Surgery, *Annals of Internal Medicine* 121:81-89,1994.
22. JS Ginsberg, C Demers, P Brill-Edwards, R Bona, M Johnston, A Wong, JA Denberg. Acquired Protein S Deficiency is Associated with Antiphospholipid Antibodies and Increased Thrombin Generation in Patients with Systemic Lupus Erythematosus, *American J. Medicine* 1995;98:379-83.
23. Frederick R. Rickles, Gregory A. Hair, Richard A. Zeff, Elizabeth Lee, Robert D. Bona. Tissue Factor Expression in Human Leukocytes and Tumor Cells, *Thrombosis and Haemostasis* 74:391-5;1995.
24. Robert Bona, Kahlil Sivjee, Amy Hickey, Donna Wallace, Selby Wajcs. The Efficacy and Safety of Oral Anticoagulants in Patients with Cancer, *Thrombosis and Haemostasis* 74:1055-58;1995.
25. Robert Bona, Amy Hickey, Lori Greenwald, Eugene Sullivan, Panos Livadiotis, Ora Johnson, Andrea Kulak, Selby Wajcs, and Kathy Vose. Low Risk of Subsequent Deep Venous Thrombosis in Patients with a Negative Venous Duplex Scan: Role of Biochemical Markers of Hypercoagulability for the Diagnosis of Deep Venous Thrombosis, *Clinical and Applied Thrombosis/Hemostasis*, 2:30-4,1996.
26. Robert Bona, Donna Wallace, Amy Hickey, Selby Wajcs. Management of Outpatient Oral Anticoagulation Therapy for the Prevention of Arterial Thrombembolism. *J of the Hoffman Heart Institute*, 2:6-9;1996.
27. John A. Heit, Scott D. Berkowitz, Robert Bona, Victor Cabanas, John Corson, C. Gregory Elliot, and Roger Lyons), Efficacy and Safety of Low Molecular Weight Heparin (Ardeparin) Compared to Warfarin for Prevention of Venous Thromboembolism Following Total Knee Replacement: a Double Blind, Dose Ranging Study, *Thromb Haemost* 1997;77:32-38.
28. Bona RD, Hickey AD, Wallace DM. Efficacy and safety of oral anticoagulation in patients with cancer. *Thromb Haemost*, 78,137-140,1997.
29. Bona, Robert, Thrombotic Complications of Central Venous Catheters in the Cancer Patient, *Seminars in Hemostasis and Thrombosis*, 1999;25:147-55.
30. Schindler J, Bona R, Chen H, Feingold J, Edwards R, Tutschka P, and Bilgrami S. Regional Thrombolysis with Urokinase for Central Venous Catheter-Related Thrombosis in Patients Undergoing High dose Chemotherapy with Autologous Stem Cell Rescue. *Clinical Applied Thrombosis and Hemostasis*, 1999;5:25-9.
31. Bilgrami S, Chakraborty NG, Rodriguez-Pinero F, Khan AM, Feingold JM, Bona RD, Edwards RL,

- Dorsky D, Clive J, Mukherji B, and Tutschka PJ. Varicella-Zoster Virus Infection Associated with High Dose Chemotherapy and Autologous Stem Cell Rescue, Bone Marrow Transplantation 1999;23:469-74.
32. Bilgrami S, Feingold JM, Dorsky D, Edwards RL, Bona RD, Khan AM, Rodriguez-Pinero F, Clive J, and Tutschka PJ. Incidence and Outcome of Clostridium difficile infection following autologous peripheral blood stem cell transplantation. Bone Marrow Transplantation 1999;23:1039-42.
  33. Bilgrami S, Aslanzadeh J, Feingold JM, Bona RD, Clive J, Dorsky D, Edwards RL, and Tutschka PJ. Cytomegalovirus viremia, viruria, and disease after autologous peripheral blood stem cell transplantation: no need for surveillance. Bone Marrow Transplantation, 1999, 24:69-73.
  34. S Bilgrami, JM Feingold, RD Bona, RL Edwards, AM Kahn, F Rodriguez-Pinero, IA Khan, D Kazierad, J Clive, and PJ Tutschka. Dose-intense paclitaxel, etoposide, and cyclophosphamide: a safe and active regimen for tumor cytoreduction and stem cell mobilization in metastatic breast cancer. Bone Marrow Transplantation 2000;25:123-30.
  35. D Kapur, D Dorsky, JM Feingold, RD Bona, RL Edwards, J Aslanzadeh, PJ Tutschka. Incidence and outcome of vancomycin-resistant enterococcal bacteremia following autologous peripheral blood stem cell transplantation. Bone Marrow Transplantation 2000;25:147-52.
  36. S Bilgrami, JM Feingold, D Kapur, RD Bona, RL Edwards, AM Khan, F Rodriguez-Pinero and PJ Tutschka. A Novel Combination of Paclitaxel, Etoposide, and Cyclophosphamide for Stem Cell Mobilization and Tumor Cytoreduction in Ovarian Cancer. J of Hematotherapy and Stem Cell Research. 2000;9:133-35.
  37. Bona RD, Hickey A, Wallace D. Warfarin is Safe as Secondary Prophylaxis for Venous Thrombosis in Patients with Cancer, Am J Clin Oncol, 2000;23:71-3.
  38. DeMedeiros BC, Rezuke WN, Ricci A, Tsongalis G, Shen PUF, Bona RD, Feingold JM, Edwards, RL, Tutschka PJ, Bilgrami. Kaposi's sarcoma following allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia, Acta Haematologica, 2000;104:115-18.
  39. Bilgrami S, Metersky M, McNally D, Kapur D, Raible D, Bona R, Edwards, R, Feingold J, Tutschka P. Idiopathic pneumonia syndrome following busulfan containing myeloablative chemotherapy and autologous peripheral blood stem cell transplantation. The Annals of Pharmacotherapy 2001;35:196-201.
  40. B Naqvi, D. Dorsky, SA Ali, JM Feingold, RL Edwards, RD Bona, J Clive, PJ Tutschka, S Bilgrami. Efficacy of Clarithromycin in the prevention of viridans streptococcal bacteremia following autologous peripheral blood stem cell transplantation. Infection, 2001;29:201-04.
  41. Tutschka PJ, Bilgrami SA, Feingold JM, Edwards RL, Bona RD, Naqvi B, Clive J. Cytoreduction and Stem Cell Mobilization with a Regimen of Paclitaxel, Etoposide, and Cyclophosphamide Followed by Autologous Transplantation Using a Preparative Regimen of Busulfan, Etoposide, and Cyclophosphamide for Patients with Advanced Lymphoma. Act Haematologica 2001(July);105:222-32.

42. Bilgrami S, Bona RD, Edwards RL, Li Z, Naqvi B, Shaikh, Furlong F, Fox J, Clive J, Tutschka P. Dexamethasone, paclitaxel, etoposide, cyclophosphamide (d-TEC) and G-CSF for stem cell mobilization in multiple myeloma. *Bone Marrow Transplantation* 2001(Aug);28:137-43.
43. Saif NW, Bona R, Greenberg, B. AIDS and thrombosis: retrospective study of 131 HIV infected patients. *AIDS Patient Care STDS* 2001 Jun;15(6):311-20.
44. R. Bona, Central vein thrombosis in patients with cancer. *Current Opinions in Pulmonary Medicine*, 2003 (September) 9:362-66.
45. Smaradottir and R. Bona. A case of acquired von Willebrand syndrome successfully treated with recombinant Factor VIIa during thyroidectomy. *Thrombosis and Hemostasis*, 2004;92:666-7.
46. Zihai Li, Yi Qiao, Bei Liu, Elizabeth Laska, Priyamvada Chakravarthi, Judith Kulko, Robert Bona, Min Fang, Upendra Hegde, Victor Moyo, Susan Tannenbaum, Antoine Menoret, Judy Gaffney, Laura Glynn, Carolyn Runowicz, Pramod Srivastava. Combination of imatinib mesylate with autologous leukocyte derived heat shock protein 70 induces immunologic and clinical responses against chronic myelogenous leukemia, *Clinical Cancer Research* 2005;11:4460-68.
47. Shahzad Shafique, Robert Bona, Andre Kaplan. Therapeutic leukapheresis in an adult with chronic myelogenous leukemia presenting with hyperleukocytosis and leukostasis. *Therapeutic Apheresis and Dialysis* 2007;11:146-48.
48. Fabio Aglieco, Srimathi Manickaratnam, Robert Bona, Andre Kaplan. A Case Report of Refractory Warm Autoimmune Hemolytic Anemia Treated with Plasmapheresis and Rituximab, *Therapeutic Apheresis and Dialysis*, 2008;12:185-89.
49. Acquired Deficiency of Vitamin K-Dependent Clotting Factors Due to Brodifacoum Ingestion, Pragna Kapadia, Robert Bona, *Connecticut Medicine* 2008;72:207-09.
50. Saad Z. Usmani, Robert Bona, Zihai Li. 17 AAG as an Hsp90 Inhibitor in Cancer – From bench to bedside, *Current Molecular Medicine*, in press.

## **Abstracts**

1. Rao KR, Robert NJ, Bona RD, Zablow B, and Pena Y, Cortical Blindness Secondary to Cancer Chemotherapy, 35th Annual Conference of Neurological Society of India.
2. Bona RD, Fair DS, and Rickles FR, Unique Activation of Factor VII in Thrombotic Thrombocytopenic Purpura, *Clinical Research*, 34 452A,1986.
3. Bona RD, Lee EJ, Rickles FR, Transport of Tissue Factor to Membrane Vesicles: Role of n-Linked Glycosylation, *Clinical Research*, 34, 655A,1986.

4. Bona RD, Fair DS, Rickles FR. Proteolytic Cleavage of Factor VII in Thrombotic Thrombocytopenic Purpura. *Circulation* 74, Supplement II, November 1986.
5. Weinstein RE, Bona RD Carta CA, and Rickles FR. Cryoprecipitate Resistant, DDAVP Responsive von Willebrand's Disease, *Circulation*, 74, Supplement II-92, 1986 (November).
6. Rickles FR, Bona RD, Lee E, Matthews E, Alberghini TV, Carta C, and Hancock W. Post-translational Modification of Human Cellular Tissue Factor. *Blood Supplement* 70:394a,1987 (November).
7. Weinstein RE, Bona RD, Weisman SJ, Quinn J, Altman AJ, and Rickles FR. Prognostic Utility of T4 Cell Count in Patients with Hemophilia. National Hemophilia Foundation, October 1988.
8. Bona RD, Matthews EM, Patel D, Carta CA, Hancock WH, and Rickles FR, Functional and Immunological Characterization of Human Tumor Procoagulants, *Clinical Res.* 37,465a,1989.
9. Bona RD, Rickles FR, Hanna WT, Weinstein RE, Carta CA, Zimmerman CE, and Rousell R. Characterization of von Willebrand Factor in Factor VIII Products. *Blood Supplement*, 74,134a, 1989 (November)
10. Bona RD, Rickles FR, Hanna Y, Weinstein RA, Carta CA, Zimmerman CE, Mull G, and rousell R. In Vitro Characterization and in vivo Receovery of von Willebrand Factor in Factor VIII Products. *Transfusion* 30,279,1990.
11. Parke AL, Weinstein RE, Bona RD, Walker FJ. The Thrombotic Diathesis Associated with Antiphospholipid Antibodies may be due to Low Levels of Free Protein S. *Clinical Research* 38,388A,1990.
12. Bona RD, Weinstein RE, Walker FJ. Pseudo Protein S Deficiency Due to a Defect in C4bp. *Blood Supplement* 76,500a,1990 (November).
13. Clarke BJ, Ofosu FA, SridharaS, Bona RD, Rickles FR, and Blajchman MA. The First Epidermal Growth Factor-Like Domain of Human Coagulation Factor VII is Essential for Complex Formation with Tissue Factor. *Blood Supplement* 76,502a,1990 (November).
14. Spiro TE and the Enoxaparin Clinical Trial Group A Randomized Trial of Enoxaparin Administration Post Operatively for the Prevention of Deep Vein Thrombosis Following Elective Hip Replacement Surgery, *Thrombosis and Haemostasis*, June 1991.
15. Dhami M, Bona RD, Hellman RM. High Grade Gliomas and Venous Thromboembolic Complications. *Proc. ASCO* 11,435,1992.
16. S. Seremetis, LM Aledort, R. Bona, G. Bray, D. Brettler, E. Eyster, C. Kessler, J Lusher, F. Rickles, H Sacks. A Three Year Randomized Prospective Study of High or Intermediate Purity Factor VIII Concentrates in Asymptomatic HIV+ Hemophiliacs: Effect on Immune Function. *Blood Suppl* 80 366a,1992 (November 15).

17. Morse EE, Panek S, Pisciotto P, Bona R, Vose K, and Rickles F. The Reemergence of the International Normalized Ratio (INR) as a Tool in the Care of Patients Receiving Anticoagulant Therapy. Association of Clinical Scientists, May 1992.
18. Parke, D. Wilson, S. Wajcs, and R. Bona. Complement Activation and low levels of free protein S are features of the primary phospholipid antibody syndrome. *Arth Rheum* 35(9):S70,1992.
19. JS Ginsberg, C Demers, P Brill-Edwards, M Johnston, R Bona, R Burrows, J Weitz, JA Denburg. Increased Thrombin Generation and Activity in Patients with Systemic Lupus Erythematosus and Anticardiolipin Antibodies; Evidence for a Prothrombotic State, Thrombosis and Haemostasis, 69;954,1993.
20. JS Ginsberg, P Brill-Edwards, M Johnston, C Demers, R Bona, A Wong, J Denburg. Low Free Protein S Levels in Patients with Systemic Lupus Erythematosus, Thrombosis and Haemostasis, 69;1227,1993.
21. Morse EE, Panek S, Pisciotto P, Kiraly T, Bona R, Vose K, and Rickles F. Patients Followed by International Normalized Ratio (INR) Have Less Variability in Prothrombin Time (PT). Association of Clinical Scientists May 1993.
22. R Bona, A Hickey, L Greenwald, E Johnson, P Livadiotis, O Johnson, A Kulak S Wajcs, K Vose. Utility of the Venous Duplex Scan and Biochemical Markers of Hypercoagulability for the Diagnosis of Deep Vein Thrombosis, Thrombosis and Haemostasis, 69;1357,1993.
23. Godwin JE, Comp P, Davidson B, Rossi M, and the Normiflo Cancer Clinical Trial Group, Comparison of the Efficacy and Safety of Subcutaneous RD Heparin VS Subcutaneous Unfractionated Heparin for the Prevention of Deep Vein Thrombosis in Patients Undergoing Abdominal or Pelvic Surgery for Cancer, Thrombosis and Haemostasis 69;647,1993.
24. TE Spiro, CW Colwell, RD Bona, AA Trowbridge, GR Wise, KW Furman, MA Ritter. A Clinical Trial Comparing the Efficacy and Safety of Enoxaparin, a Low Molecular Weight Heparin, and Unfractionated Heparin for the Prevention of Deep Venous Thrombosis After Elective Knee Replacement. *Blood (Suppl)*82;1624,1993.
25. R. Bona, K. Sivjee, D. Wallace, A. Hickey, and S. Wajcs. Safety and Efficacy of Warfarin Sodium in Patients with Cancer, *Blood* 84,674,1994.
26. J Heit, S. Berkowitz, R. Bona, P Comp, J Corson, F Cushner, G Elliott, J Garino, R Lyons, J Ohar, S Holloway, L Zaoutis, for the Ardeparin Arthroplasty Study Group. Efficacy and Safety of Normiflo (a LMWH) Compared to Warfarin for Prevention of Venous Thromboembolism Following Total Knee Replacement: A Double-Blind Dose Ranging Study. *Thrombosis and Haemostasis* 73:978;1995.
27. R. Bona and I. Kahn. Intermittent Pneumatic Compression Stockings in the Prevention of Postoperative Venous Thromboembolism. *Blood Supplement* 86,914a,1995 (Nov).
28. R. Bona, D. Wallace, A. Hickey, S. Wajcs. Thrombin Generation and Activity are Increased in Patients with Cancer Receiving Sodium Warfarin as Secondary Prophylaxis Against Venous Thrombosis. *Blood Supplement* 1997 (Nov).

29. Enoxaparin Clinical Trials Group. A Double Blind Placebo Controlled Trial Comparing the Efficacy and Safety of Prolonged Outpatient Enoxaparin and Placebo Therapies in the Prevention of Venous Thromboembolic Disease in Patients Undergoing Elective Primary Hip or Knee Replacement. *Blood Supplement* 1997 (Nov).
30. Bilgrami S, Feingold JM, Bona R, et al. Etoposide 60mg/kg, cyclophosphamide 3g/m<sup>2</sup> and paclitaxel 200mg/m<sup>2</sup>. A safe and active regimen for tumor cytoreduction and stem cell mobilization in metastatic breast cancer. *Ann Oncol* Vol. 9 suppl. 4, 1998.
31. RD Bona, RL Edwards, P Shankar, SA Bilgrami, JM Feingold, PJ Tutschka. Decadron, Taxol, Etoposide, and Cyclophosphamide (DTEC) is an Effective Chemotherapy Regimen for Stem Cell Mobilization and Tumor Reduction in Patients with Advanced Multiple Myeloma. *Blood (Suppl)* Nov. 1999.
32. N Chakraborty, PJ Tutschka, SA Bilgrami, RD Bona, JM Feingold, RL Edwards, B Mukherji. Rapid Restoration of Immune Function After Autologous Stem Cell Transplantation by Adoptive Transfer of Mature Donor Lymphocytes. *Blood (Suppl)* Nov 1999.
33. Li Z, Bilgrami S, Edwards RL, Bona RD, Gran D, Aggarwal A, Menoret A, Srivastava PK, Tutschka PJ. A feasibility study of autologous tumor - derived HSP70 vaccination against chemotherapy - resistant metastatic breast cancer. *Cell Stress and Chaperones* 5(4):390,2000.
34. Z. Li, Y Qiao, E Laska, J. Kulko, R. Bona, J. Gaffney, U. Hegde, V. Moyo, P. Srivastava. Combination of imatinib mesylate with autologous leukocyte-derived heat shock protein 70 vaccine for chronic myelogenous leukemia. *American Soc Clin Oncol*, 2003, abstract no. 664.
35. Smaradottir, L. Fritts, R. Bona. A case of acquired von Willebrand syndrome successfully treated with recombinant Factor VIIa during thyroidectomy. *Thrombosis and Hemostasis*, July 2003.
36. Chakravarthi P, Li Z, Edwards R, Altman A, Bilgrami S, Bona R, Tutschka P. Temozolomide for Acute Myelogenous Leukemia After Failure of Stem Cell Transplantation, *Proc American Society of Oncology* 2003.
37. Stolz T, Bona R, Pisciotto P. Analysis of the Reproducibility of Whole-Blood Lumiaggregometry Among Patients with Suspected Platelet Disorders and Long-term Controls. *Blood (Suppl)*, November 2003.
38. Bhatia, S and Bona, R. Iron Overload in Congenital Erythrocyte Pyruvate Kinase Deficiency. *Blood (Suppl)*, November 2003.
39. Li Z, Qiao Y, Laska E, Liu B, Glynn L, Kulko J, Bona R, Gaffney J, Hegde U, Moyo M, Srivastava P. Autologous Leukocyte Derived Heat Shock Protein 70-Peptide Complex as A Vaccine for Chronic Myelogenous Leukemia in Chronic Phase: An Updated Phase I Study. *Blood (Suppl)*, November 2003.
40. Pfeiffer CA, Kosowicz LY, Harrington K, Henry D, Bona R. Communication Skills for Assessing Pain, *AAMC Annual Meeting*, Washington, DC. November 2006.

41. Pfeiffer C, Willis M, Kosowicz L, Harrington K, Henry D, Bona R. Communication Skills for Negotiating Pain Management. International Ottawa Conference on Medical Education. May 2006.
42. Fang M, Roper N, Walsh S, Bona R. Validation of Warfarin Pharmacogenetic Testing and Dosing Algorithm. Association for Molecular Pathology, poster presentation.